These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 33498251)

  • 1. Minimal Residual Disease, Metastasis and Immunity.
    Badia-Ramentol J; Linares J; Gómez-Llonin A; Calon A
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33498251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.
    Tachtsidis A; McInnes LM; Jacobsen N; Thompson EW; Saunders CM
    Clin Exp Metastasis; 2016 Aug; 33(6):521-50. PubMed ID: 27189371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular dormancy in minimal residual disease following targeted therapy.
    Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
    Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity.
    Nicolini A; Rossi G; Ferrari P; Carpi A
    Semin Cancer Biol; 2022 Feb; 79():68-82. PubMed ID: 32201368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease in Prostate Cancer.
    Cackowski FC; Taichman RS
    Adv Exp Med Biol; 2018; 1100():47-53. PubMed ID: 30411259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer.
    Sproll C; Fluegen G; Stoecklein NH
    Adv Exp Med Biol; 2018; 1100():55-82. PubMed ID: 30411260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy.
    Sai B; Xiang J
    J Cell Mol Med; 2018 Dec; 22(12):5776-5786. PubMed ID: 30255991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Cell Dormancy in Metastasis.
    Summers MA; McDonald MM; Croucher PI
    Cold Spring Harb Perspect Med; 2020 Apr; 10(4):. PubMed ID: 31548220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy.
    Walter VP; Taran FA; Wallwiener M; Hahn M; Brucker SY; Hartkopf AD
    Arch Gynecol Obstet; 2018 Mar; 297(3):785-790. PubMed ID: 29380106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme.
    Chistiakov DA; Chekhonin VP
    Exp Mol Pathol; 2018 Oct; 105(2):166-174. PubMed ID: 30028961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating and disseminated tumor cells: harbingers or initiators of metastasis?
    Dasgupta A; Lim AR; Ghajar CM
    Mol Oncol; 2017 Jan; 11(1):40-61. PubMed ID: 28085223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor dormancy: long-term survival in a hostile environment.
    Quesnel B
    Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
    Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
    BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell dissemination: emerging biological insights from animal models and cancer patients.
    Kang Y; Pantel K
    Cancer Cell; 2013 May; 23(5):573-81. PubMed ID: 23680145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between Dormant Cancer Cells and Their Microenvironment.
    Linde N; Fluegen G; Aguirre-Ghiso JA
    Adv Cancer Res; 2016; 132():45-71. PubMed ID: 27613129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecology and evolution of dormant metastasis.
    Blasco MT; Espuny I; Gomis RR
    Trends Cancer; 2022 Jul; 8(7):570-582. PubMed ID: 35370115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology and significance of circulating and disseminated tumour cells in colorectal cancer.
    Steinert G; Schölch S; Koch M; Weitz J
    Langenbecks Arch Surg; 2012 Apr; 397(4):535-42. PubMed ID: 22350614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.